Cell-free DNA analysis reveals POLR1D-mediated resistance to bevacizumab in colorectal cancer

BACKGROUND: Bevacizumab, a monoclonal antibody against soluble VEGFA, is an approved and commonly administered anti-angiogenic drug in patients with metastasized colorectal cancer (mCRC). The survival benefit of anti-VEGF therapy in mCRC patients is limited to a few months, and acquired resistance m...

Full description

Saved in:
Bibliographic Details
Published in:Genome Med
Main Authors: Zhou, Qing, Perakis, Samantha O., Ulz, Peter, Mohan, Sumitra, Riedl, Jakob M., Talakic, Emina, Lax, Sigurd, Tötsch, Martin, Hoefler, Gerald, Bauernhofer, Thomas, Pichler, Martin, Gerger, Armin, Geigl, Jochen B., Heitzer, Ellen, Speicher, Michael R.
Format: Artigo
Language:Inglês
Published: BioMed Central 2020
Subjects:
Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7036260/
https://ncbi.nlm.nih.gov/pubmed/32087735
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13073-020-0719-6
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items